NCT07268690

Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma

Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma: A Phase III Randomized Non-Inferiority Trial

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 474 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study will evaluate whether omitting Level Va irradiation in patients without these risk features does not compromise regional control or survival, with the goal of providing robust evidence to guide further personalization of NPC radiotherapy.

Conditions

• Nasopharyngeal Carcinoma by AJCC V9 Stage

Interventions

Type	Name	Description
RADIATION	Omission of Level Va Irradiation in Nasopharyngeal Carcinoma	Level Va should be irradiated only in the presence of any of the following high-risk features: 1. Ipsilateral Level IIb involvement; 2. Ipsilateral Level III nodes involvement; 3. Ipsilateral positive lymph nodes below the cricoid cartilage (Level IV or Vb-c).

Timeline

• Start date: 2026-01-01
• Primary completion: 2028-12-31
• Completion: 2030-12-31
• First posted: 2025-12-08
• Last updated: 2025-12-08

Locations

1 site across 1 country: China